BCL2A1 and diabetes mellitus: In this issue of Diabetologia, Rolandsson and colleagues have leveraged two of these three markers, i.e. GADA and GRS, in European Prospective Investigation into Cancer and Nutrition (EPIC), a large cohort of individuals (over 340,000 participants over 40 years of age and free of known diabetes at baseline), followed for 10 years to determine the potential for these markers to identify those at risk of diabetes [4].